重大事件即時報告 8-K 2026-07-22

NRx Pharmaceuticals子公司獲DARPA選中，就SPARC-TMS臨床試驗展開合約談判

AI 繁中摘要

🇺🇸 NRx Pharmaceuticals（納斯達克：NRXP）於2026年7月21日提交8-K表格，披露其子公司NRX Defense Systems（NRXD）獲美國國防高級研究計劃局（DARPA）選中，就一項名為「突觸可塑性增強快速迴路刺激（SPARC-TMS）」的臨床試驗展開合約談判。

📋 重點事件：
- 提案獲DARPA國防科學辦公室（DSO）選中，進入合約協商階段，但尚未構成正式獎勵或授權開支。
- SPARC-TMS試驗為FDA批准的2/3期研究（ClinicalTrials.gov編號NCT07227103），旨在評估機械臂導航經顱磁刺激（TMS）結合NRX-101（D-cycloserine/lurasidone複方）對抑鬱症緩解的效果。
- NRX-101已獲FDA突破性療法認定，由NRx Pharmaceuticals自主研發並持有專利。
- 試驗計劃在哈佛大學McLean醫院、HOPE Therapeutics診所及指定軍事醫療機構（包括Walter Reed國家軍事醫療中心）進行。

💡 對投資者的潛在意義：
- 正面信號：DARPA選中提案，反映技術與臨床價值獲國防尖端科研機構認可，有望進一步拓展政府及軍事研究經費來源。
- 風險提示：目前僅為談判階段，不保證最終獲獎；合約條款、撥款金額與時間表仍屬不確定。
- 長期戰略：NRXD專注神經可塑性治療，結合D-cycloserine與機器人TMS，若成功將有助於NRx在精神疾病領域的商業化佈局。

📌 總結：消息偏正面，但投資者需留意後續談判進展與實際撥款結果。公司將持續更新合約協商狀況。

展開英文正文

nrxp20260722_8k.htm
 

 
 

false
0001719406

0001719406

2026-07-21
2026-07-21

  

 UNITED STATES 

 SECURITIES AND EXCHANGE COMMISSION 

 WASHINGTON, D.C. 20549
 

  

 FORM 8-K
 

  

 CURRENT REPORT 

 PURSUANT TO SECTION 13 OR 15(d) OF THE 

 SECURITIES EXCHANGE ACT OF 1934
 

  

 Date of Report (Date of earliest event reported) July 21, 2026
 

  

 NRX PHARMACEUTICALS, INC.
 

 (Exact name of registrant as specified in its charter)

  

 
 Delaware
 
001-38302
 
82-2844431

 

 (State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)

 

 
  

 
 1201 Orange Street, Suite 600
Wilmington, Delaware 19801

 

 (Address of principal executive offices) (Zip Code)

 

 
  

 (484) 254-6134
 

 (Registrant’s telephone number, including area code)

  

 N/A
 

 (Former name or former address, if changed since last report.)

  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

 
 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
  

 Securities registered pursuant to Section 12(b) of the Act:

  

 
 Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered

 

 Common Stock, par value $0.001 per share
 
NRXP
 
The Nasdaq Stock Market LLC

 

 
  

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company ☐
 

  

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

 
 

 
 

 

  

 
 Item 8.01.
Other Events.

 

 
  

 In April 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced the incorporation of NRx Defense Systems, Inc. (“NRXD”), a Florida-based research and development subsidiary charged with the development of neuroplastic treatments that combine D-cycloserine with Transcranial Magnetic Stimulation (“TMS”) under robotic-enabled neuro-navigation, using already developed technology. The Company anticipated NRXD participating in future government and non-governmental research and development, based on phase I and II research conducted by the Company’s Chief Medical Innovation Officer.

  

 On July 21, 2026, NRXD received a letter from the Defense Advanced Research Projects Agency (“DARPA”), Defense Sciences Office (DSO), notifying the Company that its proposal to conduct a clinical trial, entitled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) had been selected by DARPA for negotiation of a potential award.

  

 The protocol for the SPARC-TMS trial was approved as a phase 2/3 trial by the US Food and Drug Administration (FDA) and is posted on www.clinicaltrials.gov (NCT07227103). The trial aims to demonstrate the potential efficacy of robotic-enabled Transcranial Magnetic Stimulation combined with NRX-101 (combined D-cycloserine/lurasidone) in achieving remission from depression. NRX-101 which is patented by the Company was previously awarded Breakthrough Therapy Designation by the FDA. The study is planned to be conducted at Harvard Mclean hospital, at clinics operated by HOPE Therapeutics, and at designated military treatment facilities including the Walter Reed National Military Medical Center.

  

 The selection of the Company’s proposal for contract negotiation does not constitute a notice of award, a commitment by DARPA to make an award or an authorization for the Company to incur costs. Any potential award remains subject to the successful negotiation of definitive terms between DARPA/DSO and NRXD.

  

 
 

 
 

 

  

 SIGNATURE
 

  

 Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  

 
  
NRX PHARMACEUTICALS, INC.
 

 

  
 
 

 

 Date: July 22, 2026
By:
/s/ Jonathan Javitt
 

 

  
Name:
Jonathan Javitt
 

 

  
Title:
Chief Executive Officer